<DOC>
	<DOCNO>NCT00728520</DOCNO>
	<brief_summary>The drug use study call Azacitidine . Azacitidine belong group drug may restore normal control cancer cell affect gene proteins body . Azacitidine approve FDA treatment Myelodysplastic Syndrome ( MDS ) , pre-leukemic bone marrow disease . The purpose study find effect drug Azacitidine Acute Myeloid Leukemia ( AML ) elderly patient .</brief_summary>
	<brief_title>Trial With Azacitidine Newly Diagnosed Acute Myelogenous Leukemia ( AML ) Veterans Administration ( VA ) Elderly Patients Not Eligible Standard Induction Therapy</brief_title>
	<detailed_description>Prior start treatment individual consider study evaluate determine eligible participate study . There certain prestudy test require : physical exam , blood test , ECG , chest x-ray , bone marrow aspirate biopsy confirm diagnosis AML . Treatment regimen consist Azacitidine IV/SQ day 1-5 every 28 day . If Azacitidine give IV give 15-40 minute . The treatment give minimum 4 treatment cycle . Blood sample take every week monitor side effect Azacitidine . A bone marrow aspirate do every 3-4 month determine response study drug disease progress . There also quality life questionnaire complete begin study every 4 week study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Diagnosis AML Elderly patient denovo AML secondary AML evolve MDS patient &gt; /= 60 decline chemotherapy currently candidate induction chemotherapy Stable WBC &lt; 10 x 109 require hydroxyurea , chemotherapy leukapheresis &gt; 4 week No corticosteroid , hydroxyurea , lowdose cytarabine , interferon , ir retinoids within 1 month No prior decitabine No valproic acid histone deacetylase inhibitor least 2 week No GCSF , GMCSF Erythropoetin within 1 month study entry No investigational agent within 28 day ECOG performance status &lt; /= 2 KPS &gt; /= 60 % Life expectancy &gt; 2 month Normal organ function = Total bilirubin &lt; /= 1.5 x ULN , AST/ALT &lt; /= 2.5 x ULN Creatinine within normal limit creatinine clearance &gt; /= 60ml/min Signed inform consent Patients ( 15 ; 17 ) M3AML Patients chemotherapy radiotherapy within 4 week prior study entry , recover adverse effect agent administer early Patients CNS involvement AML History allergic reaction attribute Azacitidine compound similar chemical use study Pregnancy Other serious medical psychiatric illness would limit survival &lt; 3 month prevent grant informed consent lead situation would limit compliance study requirement Known positive serology HIV , HIV positive patient antiretroviral therapy ineligible Active systemic bacterial , fungal viral infection Patients severe complication leukemia include limit active infection , uncontrolled infection , pneumonia , hypoxia , shock Patients advance hepatic tumor Patients poor history medical compliance Patients know platelet refractoriness</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Azacitidine</keyword>
	<keyword>Untreated</keyword>
	<keyword>Elderly</keyword>
</DOC>